Alterations in the RB1 pathway in low-grade diffuse gliomas lacking common genetic alterations

Brain Pathology

Volumn 21, Issue 6, 2011, Pages 645-651

  Kim, Young Ho ^a   Lachuer, Joel ^b   Mittelbronn, Michel ^c   Paulus, Werner ^d   Brokinkel, Benjamin ^d   Keyvani, Kathy ^e   Sure, Ulrich ^e   Wrede, Karsten ^e   Nobusawa, Sumihito ^a,f   Nakazato, Yoichi ^f   Tanaka, Yuko ^f   Vital, Anne ^g   Mariani, Luigi ^h   Ohgaki, Hiroko ^a  

^a INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^b UNIVERSITÉ DE LYON   (France)

^c Department of Neuropathology   (France)

^d UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^e UNIVERSITY HOSPITAL ESSEN   (Germany)

^f GUNMA UNIVERSITY   (Japan)

^g Bordeaux Institute of Neuroscience   (France)

^h UNIVERSITY HOSPITAL BASEL   (Switzerland)

Author keywords

diffuse glioma; IDH1; IDH2; p14 ARF; p15 INK4b; p16 INK4a; RB1; TP53

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B; MEMBRANE PROTEIN; PROTEIN P14; RB1 PROTEIN; UNCLASSIFIED DRUG;

ADULT; AGE DISTRIBUTION; ARTICLE; ASTROCYTOMA; CHILD; CHROMOSOME 13Q; CHROMOSOME 9P; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENE DELETION; GENE LOCUS; GENETICS; GLIOMA; HISTOPATHOLOGY; HOMOZYGOTE; HUMAN; LOW GRADE DIFFUSE GLIOMA; MAJOR CLINICAL STUDY; MALE; METHYLATION; OLIGODENDROGLIOMA; PRESCHOOL CHILD; SCHOOL CHILD;

ADULT; AGED; BRAIN NEOPLASMS; CHILD; CHILD, PRESCHOOL; COMPARATIVE GENOMIC HYBRIDIZATION; CYCLIN-DEPENDENT KINASE INHIBITOR P15; DNA METHYLATION; FEMALE; GENES, P16; GLIOMA; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PROMOTER REGIONS, GENETIC; RETINOBLASTOMA PROTEIN; SIGNAL TRANSDUCTION; YOUNG ADULT;

EID: 80052765905     PISSN: 10156305     EISSN: 17503639     Source Type: Journal    
DOI: 10.1111/j.1750-3639.2011.00492.x     Document Type: Article

References (29)

1. Backlund LM, Nilsson BR, Goike HM, Schmidt EE, Liu L, Ichimura K, Collins VP, (2003) Short postoperative survival for glioblastoma patients with a dysfunctional Rb1 pathway in combination with no wild-type PTEN. Clin Cancer Res 9: 4151-4158. (Pubitemid 37204033)
2. Backlund LM, Nilsson BR, Liu L, Ichimura K, Collins VP, (2005) Mutations in Rb1 pathway-related genes are associated with poor prognosis in anaplastic astrocytomas. Br J Cancer 93: 124-130. (Pubitemid 41076260)
3. Bogler O, Huang HJ, Kleihues P, Cavenee WK, (1995) The p53 gene and its role in human brain tumors. Glia 15: 308-327.
4. Cancer Genome Atlas Research Network (2008) Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455: 1061-1068.
5. Canepa ET, Scassa ME, Ceruti JM, Marazita MC, Carcagno AL, Sirkin PF, Ogara MF, (2007) INK4 proteins, a family of mammalian CDK inhibitors with novel biological functions. IUBMB Life 59: 419-426. (Pubitemid 47123998)
6. Chano T, Ikebuchi K, Ochi Y, Tameno H, Tomita Y, Jin Y, et al, (2010) RB1CC1 activates RB1 pathway and inhibits proliferation and cologenic survival in human cancer. Plos ONE 5: e11404.
7. Collins VP, (2004) Brain tumours: classification and genes. J Neurol Neurosurg Psychiatry 75 (Suppl. 2): ii2-i11.
8. Felsberg J, Erkwoh A, Sabel MC, Kirsch L, Fimmers R, Blaschke B, et al, (2004) Oligodendroglial tumors: refinement of candidate regions on chromosome arm 1p and correlation of 1p/19q status with survival. Brain Pathol 14: 121-130. (Pubitemid 38656383)
9. Huang J, Pang J, Watanabe T, Ng HK, Ohgaki H, (2009) Whole genome amplification for array comparative genomic hybridization using DNA extracted from formalin-fixed, paraffin-embedded histological sections. J Mol Diagn 11: 109-116.
10. Kanner AA, Staugaitis SM, Castilla EA, Chernova O, Prayson RA, Vogelbaum MA, et al, (2006) The impact of genotype on outcome in oligodendroglioma: validation of the loss of chromosome arm 1p as an important factor in clinical decision making. J Neurosurg 104: 542-550.
11. Kim YH, Nobusawa S, Mittelbronn M, Paulus W, Brokinkel B, Keyvani K, et al, (2010) Molecular classification of low-grade diffuse gliomas. Am J Pathol 177: 2708-2714.
12. Kleihues P, Davis RL, Ohgaki H, Burger PC, Westphal MM, Cavenee WK, (2000) Diffuse astrocytoma. In: Pathology and Genetics of Tumours of the Nervous System, P Kleihues, WK Cavenee, (eds), Chapter pp. 22-26. IARC Press: Lyon.
13. Krouwer HG, Davis RL, Silver P, Prados M, (1991) Gemistocytic astrocytomas: a reappraisal. J Neurosurg 74: 399-406.
14. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, (eds) (2007) WHO Classification of Tumours of the Central Nervous System. IARC: Lyon.
15. McLendon RE, Enterline DS, Tien RD, Thorstad WL, Bruner JM, (1998) Tumors of central neuroepithelial origin. In: Russell and Rubinstein's Pathology of Tumors of the Nervous System, DD Bigner, RE McLendon, JM Bruner, (eds), Chapter 9 pp. 307-571. Arnold: London, Sydney, Auckland.
16. Arf deletion and methylation in genetic pathways to glioblastomas. Brain Pathol 11: 159-168. (Pubitemid 32198843)
17. Nakamura M, Yonekawa Y, Kleihues P, Ohgaki H, (2001) Promoter hypermethylation of the RB1 gene in glioblastomas. Lab Invest 81: 77-82. (Pubitemid 32108641)
18. Ohgaki H, Kleihues P, (2009) Genetic alterations and signaling pathways in the evolution of gliomas. Cancer Sci 100: 2235-2241.
19. Ortega S, Malumbres M, Barbacid M, (2002) Cyclin d-dependent kinases, INK4 inhibitors and cancer. Biochim Biophys Acta 1602: 73-87. (Pubitemid 34311901)
20. Rollbrocker B, Waha A, Louis DN, Wiestler OD, von Deimling A, (1996) Amplification of the cyclin-dependent kinase 4 (CDK4) gene is associated with high cdk4 protein levels in glioblastoma multiforme. Acta Neuropathol 92: 70-74. (Pubitemid 26192085)
21. Sasaki H, Zlatescu MC, Betensky RA, Johnk LB, Cutone AN, Cairncross JG, Louis DN, (2002) Histopathological-molecular genetic correlations in referral pathologist-diagnosed low-grade "oligodendroglioma". J Neuropathol Exp Neurol 61: 58-63. (Pubitemid 34027720)
22. Shaw EG, Daumas Duport C, Scheithauer BW, Gilbertson DT, O'Fallon JR, Earle JD, et al, (1989) Radiation therapy in the management of low-grade supratentorial astrocytomas. J Neurosurg 70: 853-861. (Pubitemid 19150501)
23. 1-phase progression. Genes Dev 13: 1501-1512. (Pubitemid 29297917)
24. Tagawa H, Karnan S, Suzuki R, Matsuo K, Zhang X, Ota A, et al, (2005) Genome-wide array-based CGH for mantle cell lymphoma: identification of homozygous deletions of the proapoptotic gene BIM. Oncogene 24: 1348-1358. (Pubitemid 40343115)
25. Tohma Y, Gratas C, Biernat W, Peraud A, Fukuda M, Yonekawa Y, et al, (1998) PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas. J Neuropathol Exp Neurol 57: 684-689. (Pubitemid 28335057)
26. Watanabe K, Tachibana O, Yonekawa Y, Kleihues P, Ohgaki H, (1997) Role of gemistocytes in astrocytoma progression. Lab Invest 76: 277-284. (Pubitemid 27082071)
27. INK4a genes in oligodendrogliomas. Acta Neuropathol 101: 185-189. (Pubitemid 32219749)
28. Watanabe T, Yokoo H, Yokoo M, Yonekawa Y, Kleihues P, Ohgaki H, (2001) Concurrent inactivation of RB1 and TP53 pathways in anaplastic oligodendrogliomas. J Neuropathol Exp Neurol 60: 1181-1189. (Pubitemid 33117098)
29. Watanabe T, Katayama Y, Yoshino A, Komine C, Yokoyama T, (2003) Deregulation of the TP53/p14ARF tumor suppressor pathway in low-grade diffuse astrocytomas and its influence on clinical course. Clin Cancer Res 9: 4884-4890. (Pubitemid 37323294)